Acumen pharmaceuticals to participate in the stifel healthcare conference

Newton, mass., nov. 11, 2024 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of alzheimer's disease, announced today that management will participate in a fireside chat at the stifel healthcare conference on monday, nov. 18, 2024, at 11:30 a.m. et.
ABOS Ratings Summary
ABOS Quant Ranking